In this Business Breakdown, David Barbato and Sean Westropp from Deep Sail Capital sit down with Precipio’s (PRPO) CEO Ilan Danieli. The company was originally profiled by Sean Westropp, aka "Deepsailcapital" on June 26, 2025, at $11.20 USD per share.

This discussion took place live on April 22nd, 2026, on the MicroCapClub Community. Join MicroCapClub and unlock the ability to listen and participate live in these discussions - https://microcapclub.com/#join

Ilan Danieli is co-founder and CEO of Precipio, a New Haven-based diagnostics company he started in 2011. Precipio runs a pathology services lab focused on blood-related cancers alongside a products division that develops molecular diagnostic assays, including a four-hour AML panel that replaces the industry-standard 10-to-15-day wait for genetic results.

In this Business Breakdown, Ilan walks through Precipio's dual model, how the clinical lab funds and accelerates product R&D (the recent BCR-ABL assay was developed for under $100,000, versus a $5–10M industry norm), and the company's 2025 inflection to profitability on 30% revenue growth. Sean Westropp, CIO of Deep Sail Capital, joins David for the Q&A, pressing Ilan on execution risk after the recent buildout of the product's sales team, unit economics, and capacity on both sides of the business, distributor go-to-market through McKesson, Fisher, Cardinal, and Medline, and the path to a 50/50 revenue mix and 80% product gross margins.

✉️ Share your feedback - david@microcapclub.com

✉️ David’s X (Twitter) - https://x.com/Valuehunte

Chapters

00:00 Introduction to Precipio and Leadership Background

05:36 Pathology Services and Product Development Synergy

11:21 Unique Business Model and Profitability

18:29 Challenges and Growth Limitations

25:58 Closing Thoughts and Industry Insights

29:16 Sales Team Success and Metrics

34:25 Identifying Niche Opportunities

36:05 Navigating Sales Cycles

37:32 Revenue Potential and Market Size

37:59 Intellectual Property and Trade Secrets

39:33 Path to Profitability

40:28 Growth Projections and Product Development

41:40 M&A Considerations

43:18 Achieving Gross Margin Targets

43:51 Internal Priorities for Growth

45:19 Barriers to Entry for Competitors

46:29 Economic Advantages of Products

48:03 Execution Risks and Market Penetration

48:31 Annual Product Development and R&D

50:48 Future Vision for the Company

Disclaimer: All content on this channel is for discussion, education, entertainment, and illustrative purposes only and SHOULD NOT be construed as professional financial advice, solicitation, or recommendation to buy or sell any securities, notwithstanding anything stated on this channel. There are risks associated with investing in securities. Loss of principal is possible. Past performance is not a predictor of future investment performance. Ian Cassel and the guests on this channel are not responsible for investment actions taken by viewers. Should you need such advice, consult a licensed financial advisor, legal advisor, or tax advisor. You agree to verify all information yourself before investing. Any past performance discussed during this program is no guarantee of future results. Investing involves risk and possible loss of principal capital; please seek advice from a licensed professional. All views expressed are personal opinions as of the date of recording and are subject to change without the responsibility to update views. No guarantee is given regarding the accuracy of the information on this channel. Releasees undertake no obligation to provide accurate or sound investment statements. You waive any and all duties that may exist flowing from you to any Releasee. You agree not to hold any Releasee liable for any possible claim for damages arising from any decision you make based on information or other content on the Channel.